Thrombosis
Latest News
Warfarin best for thrombotic antiphospholipid syndrome?
A vitamin K antagonist such as warfarin, rather than a direct oral anticoagulant, appears to be a better treatment for patients with thrombotic...
Conference Coverage
COVID update: ASH experts discuss thrombosis, immunity
Presidential symposium plumbs the mysteries of an “extraordinarily stealthy” virus, considers postvaccine blood clots.
Conference Coverage
ITP: Biologic beat placebo, but few patients improved
Exorbitant efgartigimod meets primary endpoint in only 21.8% of patients with chronic disease.
From the Journals
Statins tied to lower ICH risk regardless of bleed location
A large new case-control study has shown a reduced risk of both lobar and nonlobar intracerebral hemorrhage with statin use, providing reassurance...
Conference Coverage
For minorities with PE: Less advanced treatment, more mortality
Asians/Pacific Islanders with pulmonary embolism faced the lowest risk of hospitalization but died at the highest rate, new study finds.
Conference Coverage
No benefit of rivaroxaban in COVID outpatients: PREVENT-HD
PREVENT-HD joins a long list of smaller trials also showing no benefit of anticoagulation in nonhospitalized COVID-19 patients.
Conference Coverage
EHR-based thromboembolism risk tool boosted prophylaxis
A thromboembolism risk calculator in a hospital’s EHR led to a significant rise in appropriate thromboprophylaxis and a drop in thromboembolic...
Conference Coverage
Combo thrombolytic approach fails to reduce ICH in stroke
Although there were promising signs of a potential reduced bleeding risk in intracranial hemorrhage, the DUMAS study showed no benefit on the...
From the Journals
Best anticoagulant for minimizing bleeding risk identified
“Apixaban stood out as having lower risk of gastrointestinal bleeding.”
Conference Coverage
Collateral flow flags stroke patients for late thrombectomy
The MR CLEAN-LATE trial shows patients selected for thrombectomy on the presence of collateral flow had a greater chance of a better functional...
Feature
Apixaban outmatches rivaroxaban in patients with AFib and valvular heart disease
Compared with rivaroxaban, patients who received apixaban had a 43% reduced risk of stroke or embolism.